Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today the positive results of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term phase III placebo-controlled studies and two long-term phase III open-label studies, presented at the 2007 American Psychiatric Association (APA) annual meeting, demonstrated that GXR significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years.

"Guanfacine extended release, the first selective alpha-2A-adrenoceptor agonist to be tested in well-controlled studies as a treatment for ADHD, holds potential based on the significant improvements in ADHD symptoms documented in four studies of this investigational drug," stated co-author Joseph Biederman, M.D., lead investigator, chief of clinical and research program in pediatric psychopharmacology at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Moreover, these data presented at this medical conference add evidence that GXR when dosed once daily may continue to control children's ADHD symptoms for up to 24 months."

GXR, a nonstimulant, is not a controlled substance and does not appear to have a mechanism for potential abuse or dependence. Shire submitted a New Drug Application (NDA) for GXR on August 24, 2006, which is currently under FDA review. The NDA provided data on GXR 1 mg to 4 mg taken once daily for the treatment of children and adolescents with ADHD.

GXR Yielded Significant Reductions in ADHD-RS-IV Scores in Two Short-Term Trials

Results from two short-term, double-blind, randomized phase III clinical trials presented at this medical conference, demonstrated that GXR significantly controlled all core symptoms of ADHD, including inattention, hyperac
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/19/2009)... , LYON, France, Nov. 19 In re...pplying dangerous and illegal medicines, Operation...d by INTERPOL and the World Health Organization,s ... Taskforce (IMPACT) to highlight the dangers of bu...initiative resulted in a series of arrests and the...
(Date:11/19/2009)... , TAINAN, Taiwan, Nov. 19 /PRNewswire-A...ctive pharmaceutical ingredients (APIs), announced...Compound Safety Certification from,SafeBridge(R) C...harm,s,competency and proficiency in the safe hand...APIs), and applies to specific laboratories and,pr...
(Date:11/19/2009)... , DAYTON, Ohio, Nov. 19 Rivera...e partnering with leading Canadian medical imaging...nced Chest Imaging and OnGuard Chest Xray CAD. The... Riverain Medical,s products to the Canadian marke...le sales channel. ,, SoftView Enhanced Chest Im...
Breaking Medicine Technology:International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies 2Reportlinker Adds Infections Throat Infection 61072 1Reportlinker Adds Infections Throat Infection 61072 2Reportlinker Adds Infections Throat Infection 61072 3SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 1SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 2SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 3Reportlinker Adds Cancer Vaccines 3A Measuring Market Potential 14778 1Reportlinker Adds Cancer Vaccines 3A Measuring Market Potential 14778 2
...ence demonstrating the efficacy and safety of s...ry incontinence in women.,... in the,August issue of International Urogynecolog...udy on the safety and effectiveness of tension-fre...nary incontinence (SUI) in,women. Researchers foll...
...r Greater Concordance Compared to FISH ...pany to Include Reporting for HER2 Gene Expression... by End of 2008 -, REDWOOD CITY, Calif., Sept. 6 ...ced results from two studies demonstrating,that qu...measured by the,company,s Oncotype DX(R) breast ca...
Other Medicine Technology:New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 2New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5
(Date:11/20/2009)... Senators and Congressmen in Competit...heir Health Care Vote , W...s and congressmen running for re-election next yea...uru Charlie Cook, may come to regret voting for Ho... according to a breaking Zogby International/ O&rs...
(Date:11/20/2009)..., HAIFA, Israel, November 20 /PRNewswire-First...L.OB), http://www.CVSLMEDICAL.COM , a leading,dev...gy, today announced that,the company,s Board of Di...s,in Europe, Canada and the Far East for its propr...cable for all angioplasty (PCTA) procedures. ,,...
(Date:11/20/2009)...al published online November 20 in the Journal of...gerated fears and hopes that often appear in news ...s guidance for both the media and journals to help..., M.S., and Steven Woloshin, M.D., M.S., of Center...tute for Health Policy and Clinical Practice in Ne...
(Date:11/20/2009)... Based out of Dallas, TX, the new add...ity products that are made in the USA. , ...09 -- blue sky scrubs is an independent medical sc... design, production and distribution of hospital u...elling their products via their online boutique, t...
(Date:11/20/2009)...ivity remains high and is expected to continue, CD...News) -- Some areas of the United States are seein...ealth official said Friday, and while the disease ...the 46 states reported last week. , "We are beg...around the country, but there is still a lot of in...
Breaking Medicine News(10 mins):Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Blue Sky Scrubs Secures a Second Texas Manufacturer 2Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3
...ighly dedicated medical doctor from Connecticut wa...h. Dr. Davon Jacobson, MD has created http://heal...ng light and truth on various health topics. , ...actice, Dr. Davon Jacobson has decided to take hea...
...5 Parents can have a tremendous impact on their b...tential. By using techniques that stimulate the br...ay, they can greatly enhance the child,s awareness...y. Kang says, "A parent,s role in enhancing a chil...
...ivery of clinical data enable community hospital s...cing efficiencies. , , CHICAGO, April 5 Siemens...ced enhancements to its MedSeries4 Clinical Suit...his and other MedSeries 4 enhancements, including ...
...elps Ensure Physicians Can Access Critical Patient...l 5 From the floor of the HIMSS09 Annual Conferen...today introduced Allscripts Remote(TM), a new iPho... , , (Logo: http://www.newscom.com/cgi-bin/pr...
...ay Vacation for Two to International Destinations ...g active adults to escape to their dream destinati... a Trip of a Lifetime Sweepstakes with Move Free(R...as 10,000 secondary prizes of discount travel book...
... research by the New York University College of De... , (PRWEB) April 5, 2009 ... as well as red wine can lead to staining of the t...t allow chemicals in drinks like tea and coffee to...
Other Medicine News:Health News:Medical Doctor Enhances Health Awareness through Online Blogging 2Health News:Spotlight Baby Provides Parents with Educational Programs and Eco-Friendly Products to Support Babies in Reaching Their Full Developmental Potentials 2Health News:Community Hospitals Remain Competitive with Latest Enhancement to Siemens' MedSeries4 Clinical Suite 2Health News:Community Hospitals Remain Competitive with Latest Enhancement to Siemens' MedSeries4 Clinical Suite 3Health News:Community Hospitals Remain Competitive with Latest Enhancement to Siemens' MedSeries4 Clinical Suite 4Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 2Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 3Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 4Health News:Allscripts Introduces Electronic Health Record Capability for iPhone(TM) 5Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 2Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 3Health News:Scientists Now Warn That White Wine Can Lead To Teeth Staining 2
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: